Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

華潤醫藥集團有限公司
China Resources Pharmaceutical Group Limited
(Incorporated in Hong Kong with limited liability)
(Stock Code: 3320)

ANNOUNCEMENT

UNAUDITED FINANCIAL RESULTS OF CR SANJIU FOR THE SIX MONTHS ENDED 30 JUNE 2025

On 15 August 2025, CR Sanjiu released its interim report for the six months ended 30 June 2025.

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd（華潤三九醫藥股份有限公司）("**CR Sanjiu**") is a company incorporated in the People's Republic of China. The shares of CR Sanjiu are listed on the Shenzhen Stock Exchange. As of the date of this announcement, CR Sanjiu is indirectly owned as to 63.02% by China Resources Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") and is a subsidiary of the Company.

On 15 August 2025, CR Sanjiu released its interim report for the six months ended 30 June 2025 (the "**CR Sanjiu Unaudited Financials**"). Set out below is the key financial information of the CR Sanjiu Unaudited Financials:

	As of 30 June 2025 *(RMB)* (unaudited)	As of 31 December 2024 *(RMB)* (audited)	**Increase/Decrease** *(%)*
Total assets	**57,259,892,549.36**	40, 081,972,320.77	42.86%
Net assets attributable to shareholders of the listed company	**21,340,220,990.58**	19,903,111,306.64	7.22%

	For the six months ended 30 June		
	2025 *(RMB)* (unaudited)	**2024** *(RMB)* (unaudited)	**Increase/Decrease** *(%)*
Revenue	**14,810,160,218.62**	14,106,012,765.08	4.99%
Net profit attributable to the shareholders of the listed company	**1,815,258,362.79**	2,398,360,138.02	–24.31%
Net profit attributable to the shareholders of the listed company (after extraordinary gains or losses)	**1,697,709,126.14**	2,308,597,153.62	–26.46%
Net cash flow from operating activities	**2,860,194,941.31**	2,363,114,807.27	21.03%
Basic earnings per share *(RMB/share)*	**1.09**	1.44	–24.31%
Diluted earnings per share *(RMB/share)*	**1.09**	1.44	–24.31%
Weighted average return on net asset *(%)*	**8.80%**	12.32%	–3.52 percentage points

The CR Sanjiu Unaudited Financials have been prepared in accordance with the PRC Generally Accepted Accounting Principles, have not been reviewed or audited by the Company's auditors, and may require adjustment during the course of auditing. The financial information is limited to CR Sanjiu only and does not represent or provide a complete view of the operational or financial status of the Group. **Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.**

For further details of the CR Sanjiu Unaudited Financials, please refer to the interim report for the six months ended 30 June 2025 published by CR Sanjiu on the website of the Shenzhen Stock Exchange (www.szse.cn).

By order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 15 August 2025

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director; Mr. Tao Ran and Mdm. Deng Rong as executive Directors; Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive Directors.